All In Biotech

Drug Trial Radar · NCT03056755

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments

Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

383

Actual

Start

Aug 29, 2017

Primary completion

Jun 14, 2021

Study completion Nov 12, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase II, multicenter, open-label, three-cohort, non-comparative study of alpelisib plus endocrine therapy (either fulvestrant or letrozole) in subjects (pre- and post-menopausal women and men) with HR-positive, HER2-negative aBC harboring PIK3CA mutation(s) in the tumor, whose disease had progressed on or after prior treatments.

Conditions

  • Breast Cancer

Interventions

  • AlpelisibDrug

    300 mg of alpelisib film-coated tablets administered orally once daily

  • FulvestrantDrug

    500 mg of fulvestrant via intramuscular injection administered on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter. Cycle=28 days

  • LetrozoleDrug

    2.5 mg of letrozole film-coated tablets administered orally once daily

  • GoserelinDrug

    3.6 mg of goserelin via injectable subcutaneous implant administered every 28 days. Only for men in Cohort B and premenopausal women.

  • LeuprolideDrug

    7.5 mg of leuprolide via injectable intramuscular depot administered every 28 days. Only for men in cohort B and premenopausal women.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Core Phase: Percentage of Participants Who Were Alive Without Disease Progression at 6 MonthsTime frame: At 6 months

Locations

94 sites in 19 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Kaiser Permanente Medical Group

    Anaheim, California

  • Beverly Hills Cancer Center

    Beverly Hills, California

  • University of Calif Irvine Med Cntr

    Irvine, California

  • Kaiser Permanent Southern Californi

    San Diego, California

  • UCSF

    San Francisco, California

  • Yale University Yale Cancer Center

    New Haven, Connecticut

  • Advent Health Cancer Institute

    Orlando, Florida

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • University of Louisville James Graham Brown Cancer Center

    Louisville, Kentucky

  • Mercy Medical Center

    Baltimore, Maryland

  • Greater Baltimore Med Center Cancer Center

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Lahey Clinic

    Burlington, Massachusetts

  • Josephine Ford Cancer Center

    Detroit, Michigan

  • St Vincent Frontier Cancer Center

    Billings, Montana

  • New Mexico Cancer Care Alliance

    Albuquerque, New Mexico

  • Memorial Sloane Ketterin Cancer Ctr

    New York, New York

  • Uni Hosp of Cleveland Cancer Center

    Cleveland, Ohio

  • Texas Oncology

    Dallas, Texas

  • Cancer Care Centers of South Texas HOAST

    San Antonio, Texas

  • UT Health San Antonio

    San Antonio, Texas

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Northwest Medical Specialists

    Tacoma, Washington

  • Novartis Investigative Site

    La Rioja, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Rosario, Sante Fe, Argentina

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Liège, Belgium

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Halifax, Nova Scotia, Canada

  • Novartis Investigative Site

    Kitchener, Ontario, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Santiago, Chile

  • Novartis Investigative Site

    Santiago, Chile

  • Novartis Investigative Site

    Temuco, Araucania, Chile

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.